423
Participants
Start Date
October 31, 2008
Primary Completion Date
April 30, 2010
Study Completion Date
September 30, 2016
Cediranib
30 mg/day, oral, until progression
Cediranib
20 mg/day, oral, until progression
Lomustine Chemotherapy
110 mg/m2 / Q6W, oral, until progression
Placebo Cediranib
Oral, until progression
Research Site, Birmingham
Research Site, Pheonix
Research Site, Los Angeles
Research Site, New Haven
Research Site, Gainesville
Research Site, Jacksonville
Research Site, Chicago
Research Site, Evanston
Research Site, Kansas City
Research Site, Boston
Research Site, Detroit
Research Site, Amherst
Research Site, New York
Research Site, Cincinnati
Research Site, Cleveland
Research Site, Columbus
Research Site, Philadelphia
Research Site, Pittsburgh
Research Site, Houston
Research Site, Seattle
Research Site, Morgantown
Research Site, Camperdown
Research Site, Heidelberg
Research Site, Nedlands
Research Site, Parkville
Research Site, St Leonards
Research Site, Woodville
Research Site, Graz
Research Site, Brussels (Anderlecht)
Research Site, Brussels (Jette)
Research Site, Brussels (Woluwé-St-Lambert)
Research Site, Leuven
Research Site, Calgary
Research Site, Toronto
Research Site, Montreal
Research Site, Liberec
Research Site, Bobigny
Research Site, Marseille
Research Site, Paris
Research Site, Rennes
Research Site, Saint-Herblain
Research Site, Villejuif
Research Site, Berlin
Research Site, Bielefeld
Research Site, Dresden
Research Site, Düsseldorf
Research Site, Göttingen
Research Site, Hanover
Research Site, Heidelberg
Research Site, Kiel
Research Site, Leipzig
Research Site, Nordhausen
Research Site, Regensburg
Research Site, Amsterdam
Research Site, Groningen
Research Site, Maastricht
Research Site, Rotterdam
Research Site, The Hague
Research Site, Glasgow
Research Site, London
Research Site, Manchester
Research Site, Sutton
Lead Sponsor
AstraZeneca
INDUSTRY